On September 23, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, reported it will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the company’s wholly owned subsidiary building a multi-agentic AI platform for drug development. To register: View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CEO Panna Sharma will lead the session and will be joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of the multi-agentic platform. OMAI’s core capabilities and initial platform were built inside Lantern’s own clinical programs and areas of focus. The platform launched as withZeta.ai in April 2026, focused on rare cancers, and is now expanding into new diseases, new types of therapies, and additional stages of drug development. Today’s session will show where OMAI is going, share feedback from key user segments, and include a live demonstration of the platform’s most differentiated capabilities.
What the Webinar Will Cover
● Market: The size of the opportunity and the shift from AI pilots to full-scale adoption in drug development.
● Customers & Feedback: Who is buying, what they need, how they use the platform; and what key customer segments and power users are telling us.
● Live demo: The platform’s differentiated capabilities, shown in real time.
● Roadmap: Next generation of functionality and modules, priority disease areas, and key milestones including social and enterprise features.
● Economics: The subscription and enterprise licensing model.
● Benchmarks: How the platform performs and how performance is being measured.
● Partnerships: Types of collaborations and partnerships under discussion.
● Shareholder value: How OMAI adds to Lantern’s pipeline and long-term value.
Webinar Details
● Date and time: Today, Wednesday, September 23, 2026, 12:30 PM Eastern / 9:30 AM Pacific
● Register: View Source
● Format: 45 minutes, including a presentation and live demo followed by Q&A. Questions can be sent in advance to [email protected]
● Replay: Available on the Investors section of www.lanternpharma.com after the event
(Press release, Lantern Pharma, SEP 23, 2026, View Source [SID1234671028])